Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
U.S. Patent Office Allows Hythiam Patent Application Underlying the PROMETA Treatment Program for Alcoholism
January 25th, 2008
Hythiam, Inc. (NASDAQ:HYTM) announced that the United States Patent and Trademark Office has allowed Hythiam's U.S. Patent Application No. 10/621,229 which contains claims using a composition of matter for reducing a person's desire to drink alcohol. The patent will serve to enhance protection of the intellectual property underlying the company's PROMETA Treatment Program. This patent, the second allowance in the U.S., represents the securing of the last of the initial patents in both Europe and the U.S. To date, Hythiam has been granted or allowed 56 patents throughout the world. The company believes that just as meaningful, however, are the continuation in part...
Source: Medical Patent Business Week (2008-01-25)
|
